Utility of 2- Octyl Cyanoacrylate (2-OCA)
Launched by METHODIST HEALTH SYSTEM · Mar 3, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complication can be reduced by following the Z-track technique; however, fluid leaks still occur causing significant morbidity. 2-Octyl cyanoacrylate (2-OCA, Dermabond manufactured by Ethicon Inc) skin adhesive has been used for years for skin closure for wounds from surgical incisions including punctures from minimally invasive surgery and simple trauma lacerations. It has also been used for treatment o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inpatients at Methodist Dallas Medical Center (MDMC) ≥18 years of age with ascites requiring therapeutic paracentesis performed by the procedure team at the bedside.
- Exclusion Criteria:
- • Paracentesis procedures performed in the interventional radiology department or by physicians outside of the procedure team.
- • Patients who undergo a liver transplant surgery or other abdominal surgeries within 48 hours from the paracentesis procedure.
- • Patients that undergo paracentesis using a device or kit other than the 18 gauge Safe-T-Centesis kit
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Ahmed Alobaidi, MD
Principal Investigator
Methodist Health System
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials